N/A Completed N=54 Randomized Single-blind Treatment

The Effect of Nebivolol on Insulin Sensitivity

Hypertension

Source: ClinicalTrials.gov NCT00125853 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2019

Primary outcomePrimary: Insulin Sensitivity Index (ISI) — 82.36; 80.70; 75.47; 81.54 factor — p=0.60

Summary

The purpose of this study is to conduct a randomised trial to compare the insulin sensitivity, 24 hour blood pressure profile, and tolerability of nebivolol plus a thiazide-like diuretic versus atenolol plus a thiazide-like diuretic.

Outcome Measures

Outcome	Result	p-value
PRIMARY Insulin Sensitivity Index (ISI)	82.36; 80.70; 75.47; 81.54	0.60
SECONDARY 24 Hour Systolic Blood Pressure	128.4; 130.4; 117.2; 121.2	0.06
SECONDARY Total Cholesterol	5.0; 5.1; 4.9; 5.1	0.51
SECONDARY HbA1c	5.7; 5.7; 5.7; 5.7	0.48
SECONDARY BMI	28.1; 28.2; 28.0; 28.3	0.09

Eligibility Criteria

Inclusion Criteria

Males or females aged 18 or above
Blood pressure that meets any of the three following criteria:
BP should be <140/85 mmHg on a maximum of two anti-hypertensive drugs

Exclusion Criteria

contraindications to beta-blockade
contraindications to thiazide use
if there was a history of asthma, diabetes, heart failure, bradycardia, atrial fibrillation, AV conduction disturbances
concurrent treatment with verapamil & dilitiazem
childbearing women
compelling indication for treatment with a beta blocker
any condition that will interfere with the treatment or the patient's ability to complete the study

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00125853). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.